← Back to Search

Histamine H2 Receptor Antagonist

Study Drug for Upper Gastrointestinal Bleeding (SUPPRESS-CHD Trial)

Phase 4
Waitlist Available
Led By Kimberly I Mills, MD
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, anticipated 2 years.
Awards & highlights

SUPPRESS-CHD Trial Summary

This study is evaluating whether stress ulcer prophylaxis is safe for infants with congenital heart disease.

Eligible Conditions
  • Upper Gastrointestinal Bleeding
  • Stress Ulcers
  • Infections
  • Congenital Heart Disease

SUPPRESS-CHD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, anticipated 2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, anticipated 2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Predefined Feasibility Outcomes to Assess Trial Success
Rate of upper gastrointestinal bleeds
Secondary outcome measures
Microbiome alterations
Rate of hospital-acquired infections

SUPPRESS-CHD Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Study DrugActive Control1 Intervention
Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
Group II: PlaceboPlacebo Group1 Intervention
Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.

Find a Location

Who is running the clinical trial?

Boston Children's HospitalLead Sponsor
760 Previous Clinical Trials
5,579,610 Total Patients Enrolled
The Gerber FoundationOTHER
41 Previous Clinical Trials
5,926 Total Patients Enrolled
Kimberly I Mills, MDPrincipal InvestigatorBoston Children's Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
Kimberly I. Mills, MD 2019. "Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03667703.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top